Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase II Trial of Hypofractionated Intensity Modulated Radiation Therapy(IMRT) With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor(GM-CSF) for Patients With Newly Diagnosed Glioblastoma Multiforme.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang Cancer Hospital
• Treatments: Dacarbazine; Molgramostim; Sargramostim; Temozolomide

Criteria

Inclusion Criteria:

• Newly diagnosed and pathologically confirmed glioblastoma multiforme without an enhanced lesion beside the cerebrospinal fluid space on baseline magnetic resonance imaging

• Karnofsky performance status more than 60

• Normal liver, kidney, and bone marrow function.

Exclusion Criteria:

• Previous allergies to granulocyte macrophage colony stimulating factor

• Receiving radiotherapy

• Receiving other investigational agents

• Had uncontrolled intercurrent illnesses.